細胞療法市場：タイプ別、治療タイプ別、投与方法別、用途別、エンドユーザー別-2025-2030年の世界予測

細胞療法市場は、2024年には96億米ドルとなり、2025年には106億4,000万米ドル、CAGR 10.94%で成長し、2030年には179億1,000万米ドルに達すると予測されています。

細胞療法は現代医療における画期的な手段として登場し、さまざまな重篤な健康状態における治療パラダイムを着実に変革しています。この包括的な調査では、細胞療法が開発され、改良され、最終的に臨床現場で応用されるまでのダイナミックな環境を詳細に調査しています。バイオテクノロジーの進歩と細胞メカニズムの深い理解により、従来の治療法から生きた細胞の可能性を活用した革新的な治療法へのシフトが加速しています。本分析では、この進化の重要性を強調し、科学的ブレークスルーと市場成長を牽引する商業的原動力の双方に焦点を当てる。読者は、この分野のパイオニアが直面する戦略的要因、主要な促進要因、潜在的課題について、包括的な見解を得ることができます。本レポートは、進化する規制状況や画期的な科学的洞察など、市場の複雑さを掘り下げることで、細胞治療が将来の治療法をどのように形成しつつあるのかを理解するための強固な基盤を築きます。本レポートの各セクションは、意思決定者や業界の専門家が、この複雑でありながら有望なフロンティアを明瞭かつ的確にナビゲートするための手引きとなるよう設計されています。

細胞治療のエコシステムを再定義する転換期

近年、細胞治療の情勢は大きな変貌を遂げ、革新は医学的に可能なことの限界を押し広げています。新たな科学的洞察と技術の進歩が融合するにつれ、この業界は研究、応用、商業化を再定義するような急激な変化を経験しています。かつては研究室にとどまっていた先駆的な治療法は、技術や臨床インフラへの多額の投資によって、現実の世界への応用へと向かっています。この変革は、治療が個々の患者のプロファイルに合わせてますますカスタマイズされるようになる精密医療の統合によって顕著に表れています。これと並行して、細胞工学の新しい手法が治療介入の効率と安全性を高め、より的を絞った制御された応用への道を開いています。世界中の規制の枠組みは、技術革新の急速なペースを反映し、安全基準が新たな技術に追いつけるよう、進化を始めています。学界、バイオテクノロジー企業、大規模製造企業間の共同研究は、研究開発イニシアチブをさらに加速させています。こうしたシフトが相まって、市場は、確立されたプロトコールが革新的なアプローチによって絶えず課題され、研究への持続的投資が長期的な成功に不可欠となる、新たな時代へと押し上げられています。

細胞治療市場の詳細なセグメンテーション洞察

細胞治療市場の分析には、その複雑なセグメンテーションの微妙な理解が必要です。本調査では、いくつかの極めて重要な基準に基づき、その状況を検証しています。まず、市場をタイプ別に区分すると、非幹細胞と幹細胞に分けられます。非幹細胞はさらに、CAR-T細胞、樹状細胞、NK細胞などのセグメントに分けられ、それぞれが独自の臨床的優位性と治療の多様性を示しています。対照的に、幹細胞セグメントは、多様な治療の可能性を提供する胚性幹細胞、造血幹細胞、間葉系幹細胞を含む細分化されたセグメントを通して厳密に調査しています。分析では次に、治療の種類を掘り下げ、同種療法と自家療法に分類しています。各療法タイプは臨床応用だけでなく、製造の複雑さや規制監督も異なるため、この区別は非常に重要です。さらに分析を深めるため、市場は投与方法によって区分され、筋肉内、腫瘍内、静脈内投与などの方法が検討されています。これらの方法に関連するさまざまな有効性と安全性プロファイルには、臨床上の嗜好や物流上の課題を明確に理解する必要があります。さらに、アプリケーションベースのセグメンテーションは、多様な病態における機会を発見します。主な応用分野は、自己免疫疾患、がん治療、感染症、再生医療などです。これらのうち、自己免疫疾患では多発性硬化症や関節リウマチ、がん治療では血液悪性腫瘍や固形腫瘍、感染症では細菌感染とウイルス感染の区別といったサブ分野まで詳細に調査しています。最後に、エンドユーザー別のセグメンテーションでは、市場需要を牽引する学術・研究機関、診療所、商業研究所、病院の役割を明らかにします。各セグメントは、需要と技術革新に影響を与える独自の要因によって形成されており、市場のダイナミクスと将来の成長軌道をより深く理解するのに役立ちます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんや心血管疾患などの慢性疾患の罹患率が増加
    • さまざまな地域における政府の支援政策と資金援助
    • 消費者とヘルスケア専門家の意識の高まりは、細胞療法の重要性を強調しています。
  • 抑制要因
    • 細胞療法治療の高額な費用により、より幅広い患者層へのアクセスが制限されている
  • 機会
    • 遺伝子編集技術の利用拡大により治療能力が変革
    • バイオテクノロジー企業と学術機関の研究開発および連携への投資の増加
  • 課題
    • 細胞治療における一貫性と拡張性の維持に関する問題
• 市場セグメンテーション分析
  • タイプ：特定の血液がんの治療における非幹細胞の好ましさの高まり
  • エンドユーザー：高度な治療を提供するクリニックでの細胞療法の使用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 細胞療法市場：タイプ別

• 非幹細胞
  • CAR-T細胞
  • 樹状細胞
  • NK細胞
• 幹細胞
  • 胚性幹細胞
  • 造血幹細胞
  • 間葉系幹細胞

第7章 細胞療法市場治療の種類別

• 同種異系
• 自家移植

第8章 細胞療法市場投与方法別

• 筋肉内
• 腫瘍内
• 静脈内

第9章 細胞療法市場：用途別

• 自己免疫疾患
  • 多発性硬化症
  • 関節リウマチ
• がん治療
  • 造血悪性腫瘍
  • 固形腫瘍
• 感染症
  • 細菌感染症
  • ウイルス感染
• 再生医療

第10章 細胞療法市場：エンドユーザー別

• 学術調査機関
• クリニック
• 商業研究所
• 病院

第11章 南北アメリカの細胞療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の細胞療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの細胞療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Anterogen Co., Ltd.
• Astellas Pharma Inc.
• Athersys, Inc.
• BioNTech SE
• Bristol-Myers Squibb Company
• Castle Creek Biosciences, Inc.
• Catalent, Inc.
• FUJIFILM Holdings Corporation
• Gilead Sciences, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Kolon TissueGene, Inc.
• Lonza Group Ltd.
• Medipost Co., Ltd.
• Mesoblast Ltd.
• Novartis AG
• NuVasive, Inc.
• Pfizer Inc.
• Sartorius AG
• Stemedica Cell Technologies, Inc.
• Stempeutics Research Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• TegoScience
• Thermo Fisher Scientific, Inc.
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. CELL THERAPY MARKET MULTI-CURRENCY
• FIGURE 2. CELL THERAPY MARKET MULTI-LANGUAGE
• FIGURE 3. CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 4. CELL THERAPY MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. CANADA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 77. CANADA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 78. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. CANADA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. CANADA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. CANADA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. CANADA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 129. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 136. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. INDIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. INDIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 139. INDIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 140. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. INDIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. INDIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. INDIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 145. INDIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 146. INDIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 288. GERMANY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 298. ISRAEL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 308. ITALY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 309. ITALY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 310. ITALY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 311. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 312. ITALY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 313. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 314. ITALY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 315. ITALY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 316. ITALY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 317. ITALY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 318. NETHERLANDS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 319. NETHERLANDS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 328. NIGERIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 329. NIGERIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 338. NORWAY CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 339. NORWAY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 340. NORWAY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 341. NORWAY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 342. NORWAY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 343. NORWAY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 344. NORWAY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 347. NORWAY CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 348. POLAND CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 349. POLAND CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 350. POLAND CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 351. POLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 352. POLAND CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 353. POLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 354. POLAND CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 355. POLAND CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 356. POLAND CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 357. POLAND CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 358. QATAR CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 359. QATAR CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 360. QATAR CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 361. QATAR CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 362. QATAR CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 363. QATAR CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 364. QATAR CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
• TABLE 365. QATAR CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
• TABLE 366. QATAR CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 367. QATAR CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 368. RUSSIA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 369. RUSSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 370. RUSSIA CELL THER

The Cell Therapy Market was valued at USD 9.60 billion in 2024 and is projected to grow to USD 10.64 billion in 2025, with a CAGR of 10.94%, reaching USD 17.91 billion by 2030.

Cell therapy has emerged as a groundbreaking avenue in modern medicine, steadily transforming treatment paradigms across a range of critical health conditions. This comprehensive study provides a detailed exploration of the dynamic environment in which cell therapies are developed, refined, and ultimately applied in clinical settings. Advancements in biotechnology and a deeper understanding of cellular mechanisms have accelerated the shift from traditional treatments to innovative therapies that harness the potential of living cells. In this analysis, we underline the importance of this evolution, highlighting both the scientific breakthroughs and the commercial impetus driving market growth. Readers will gain a well-rounded view of the strategic factors, key drivers, and potential challenges facing pioneers in this field. By delving into the market's intricacies, including evolving regulatory landscapes and breakthrough scientific insights, this report lays a robust foundation for understanding how cell therapy is shaping future treatment modalities. The ensuing sections are designed to guide decision-makers and industry experts in navigating this complex yet promising frontier with clarity and authority.

Transformative Shifts Redefining the Cell Therapy Ecosystem

The landscape of cell therapy has undergone a profound transformation over recent years, with innovation pushing the boundaries of what is medically possible. As new scientific insights and technological advancements converge, the industry is experiencing radical changes that redefine research, application, and commercialization. Pioneering therapies that were once confined to laboratories are now moving towards real-world applications, driven by significant investments in technology and clinical infrastructure. This transformation is marked by the integration of precision medicine, where treatments are increasingly customized to individual patient profiles. In parallel, new methods in cell engineering have enhanced the efficiency and safety of therapeutic interventions, paving the way for more targeted and controlled applications. Regulatory frameworks around the world have started to evolve, reflecting the swift pace of innovation and ensuring that safety standards keep up with emerging technologies. Collaborations between academia, biotechnology firms, and large-scale manufacturing entities have further accelerated research and development initiatives. Together, these shifts are propelling the market into a new era where established protocols are continuously challenged by innovative approaches, and where sustained investment in research is critical for long-term success.

Detailed Segmentation Insights in the Cell Therapy Market

Analyzing the cell therapy market requires a nuanced understanding of its complex segmentation. The study examines the landscape based on several pivotal criteria. First, when segmented by type, the market distinguishes between Non-stem Cells and Stem Cells. The Non-stem Cell category is further divided into segments such as CAR-T Cells, Dendritic Cells, and NK Cells, each demonstrating unique clinical advantages and treatment versatility. In contrast, the Stem Cell segment is rigorously studied through its subdivisions, encompassing Embryonic Stem Cells, Hematopoietic Stem Cells, and Mesenchymal Stem Cells, which offer diverse therapeutic potentials. The analysis then delves into therapy types, categorizing offerings as Allogenic or Autologous therapies. This distinction is critical, as each therapy type varies not only in clinical application but also in manufacturing complexity and regulatory oversight. Further deepening the analysis, the market is segmented according to the mode of administration, examining practices such as Intramuscular, Intratumoral, and Intravenous delivery. The varied efficacy and safety profiles associated with these methods require a clear understanding of clinical preferences and logistical challenges. Moreover, the application-based segmentation uncovers opportunities in a diverse range of medical conditions. Key application areas include Autoimmune Disorders, Cancer Treatment, Infectious Diseases, and Regenerative Medicine. Within these, detailed investigations extend to sub-fields like Multiple Sclerosis and Rheumatoid Arthritis for Autoimmune Disorders, Hematologic Malignancies and Solid Tumors for Cancer Treatment, and distinctions between Bacterial Infections and Viral Infections within Infectious Diseases. Lastly, segmentation by end user highlights the role of Academic & Research Institutes, Clinics, Commercial Laboratories, and Hospitals in driving market demand. Each segment, shaped by unique factors influencing demand and innovation, collectively contributes to a deeper understanding of market dynamics and future growth trajectories.

Based on Type, market is studied across Non-stem Cells and Stem Cells. The Non-stem Cells is further studied across CAR-T Cells, Dendritic Cells, and NK Cells. The Stem Cells is further studied across Embryonic Stem Cells, Hematopoietic Stem Cell, and Mesenchymal Stem Cell.

Based on Therapy Type, market is studied across Allogenic and Autologous.

Based on Mode of Administration, market is studied across Intramuscular, Intratumoral, and Intravenous.

Based on Application, market is studied across Autoimmune Disorders, Cancer Treatment, Infectious Diseases, and Regenerative Medicine. The Autoimmune Disorders is further studied across Multiple Sclerosis and Rheumatoid Arthritis. The Cancer Treatment is further studied across Hematologic Malignancies and Solid Tumors. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections.

Based on End User, market is studied across Academic & Research Institutes, Clinics, Commercial Laboratories, and Hospitals.

Global Regional Dynamics Shaping the Cell Therapy Market

A regional perspective reveals that the cell therapy market is not uniformly developed around the world, with distinct geographies contributing in unique ways. In the Americas, robust research ecosystems, strong clinical infrastructure, and supportive regulatory environments have positioned the region as a leader in both innovation and market adoption. Strategic investments along with well-established pharmaceutical and biotechnology sectors have provided the necessary impetus for rapid progress and successful commercialization. In contrast, the combined region of Europe, Middle East & Africa has demonstrated a strategic blend of research excellence and regulatory reform. Innovations in these parts of the world frequently reflect a balance between adherence to strict safety protocols and the agility required to embrace emerging scientific methods. Meanwhile, the Asia-Pacific region has shown remarkable growth, driven primarily by increasing healthcare expenditure and an expanding R&D landscape. Governments in these countries are actively fostering scientific collaborations and ramping up efforts to streamline clinical trials and approvals. Each region contributes distinct strengths such as technological prowess, market scale, or regulatory agility, thereby enriching the overall market architecture. These regional insights provide a holistic understanding of how local conditions can significantly influence global trends, offering a roadmap for companies looking to tailor their strategies according to geographic opportunities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Strategic Company Perspectives in the Cell Therapy Arena

Examining the competitive environment of the cell therapy market sheds light on numerous companies that have positioned themselves as innovators and key drivers for change. Several industry leaders, such as Anterogen Co., Ltd. and Astellas Pharma Inc., are at the forefront of developing advanced treatments while concurrently investing in robust research pipelines. Pioneering firms like Athersys, Inc. and BioNTech SE have propelled scientific advancements through their innovative approaches to cell-based therapies, emphasizing both efficacy and safety. Not to be overlooked, large multinational entities including Bristol-Myers Squibb Company and Novartis AG have significantly broadened their portfolios to incorporate cutting-edge cell therapeutic products. Their expansive networks facilitate collaboration across research, clinical trials, and regulatory environments. Other notable companies, such as Castle Creek Biosciences, Inc. and Catalent, Inc., contribute through precise manufacturing capabilities that enhance product scalability. Enterprises like FUJIFILM Holdings Corporation, Gilead Sciences, Inc., and JCR Pharmaceuticals Co., Ltd. continue to push the envelope with their investments in novel biological constructs. Furthermore, innovative players including Kolon TissueGene, Inc., Lonza Group Ltd., and Medipost Co., Ltd. are critical for introducing next-generation technologies that set new benchmarks in treatment efficacy. In addition, firms such as Mesoblast Ltd. and NuVasive, Inc. are expanding their research horizons and forging strategic partnerships that enable cross-sector synergy. With Pfizer Inc., Sartorius AG, Stemedica Cell Technologies, Inc., and Stempeutics Research Pvt. Ltd. collectively driving technological advancements, the market is witnessing accelerated progress alongside increased investment in state-of-the-art research facilities. Finally, Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation continue to build on this momentum, strengthening the infrastructure that underpins market growth. Together, these companies offer varied strategic narratives that collectively enrich insights into the evolving trends and competitive dynamics of the cell therapy market.

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Athersys, Inc., BioNTech SE, Bristol-Myers Squibb Company, Castle Creek Biosciences, Inc., Catalent, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., Lonza Group Ltd., Medipost Co., Ltd., Mesoblast Ltd., Novartis AG, NuVasive, Inc., Pfizer Inc., Sartorius AG, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, TegoScience, Thermo Fisher Scientific, Inc., and Vericel Corporation. Actionable Strategic Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multi-pronged strategy to navigate the challenges and opportunities in cell therapy. It is essential to invest heavily in research and development to adopt novel therapeutic approaches and improve clinical outcomes. Leaders should consider forming strategic alliances with academic institutions and specialized biotechnology firms to gain access to pioneering research and leverage emerging technologies. Embracing flexible regulatory strategies and staying informed on global policy updates can ensure readiness to adapt to sudden market shifts. Furthermore, optimizing manufacturing processes and expanding scalable operations will be critical in meeting increasing market demand. Prioritizing patient-centric innovation and streamlining clinical trial protocols can enhance both efficacy and safety, ensuring competitive differentiation in an increasingly crowded field. By focusing on these key areas, stakeholders can enhance their market positioning and secure long-term success in a rapidly evolving sector.

Conclusion and Future Outlook of the Cell Therapy Market

The analysis presents a vivid picture of a market in flux-where transformative scientific innovations, robust regional strategies, and a competitive array of companies converge to shape the future of cell therapy. Throughout this study, it has become evident that technological and regulatory advancements are recalibrating traditional clinical paradigms and offering renewed hope for addressing complex health conditions. The cumulative insights gathered provide a comprehensive overview that not only highlights current opportunities but also outlines the steps necessary for future growth. In summary, while challenges persist, the strategic convergence of investment, innovation, and collaboration appears poised to propel the cell therapy market to new heights. Decision-makers and industry specialists are now better equipped to harness these insights, guiding the sector towards more efficient, streamlined, and impactful therapeutic interventions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of chronic diseases such as cancer and cardiovascular diseases worldwide
    • 5.1.1.2. Supportive government policies and funding in various regions
    • 5.1.1.3. Rising awareness among consumers and healthcare professionals underscores the importance of cell therapy
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cell therapy treatment limiting accessibility for broader patient populations
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing utilization of gene-editing technologies transform cell therapy treatment capabilities
    • 5.1.3.2. Rising investments in R&D and collaborations between biotech companies and academic institutions
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to maintaining consistency and scalability in cell therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising preference for non-stem cells to treat certain blood cancers
  • 5.2.2. End User: Rising use of cell therapy in clinics to deliver advanced treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell Therapy Market, by Type

• 6.1. Introduction
• 6.2. Non-stem Cells
  • 6.2.1. CAR-T Cells
  • 6.2.2. Dendritic Cells
  • 6.2.3. NK Cells
• 6.3. Stem Cells
  • 6.3.1. Embryonic Stem Cells
  • 6.3.2. Hematopoietic Stem Cell
  • 6.3.3. Mesenchymal Stem Cell

7. Cell Therapy Market, by Therapy Type

• 7.1. Introduction
• 7.2. Allogenic
• 7.3. Autologous

8. Cell Therapy Market, by Mode of Administration

• 8.1. Introduction
• 8.2. Intramuscular
• 8.3. Intratumoral
• 8.4. Intravenous

9. Cell Therapy Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Disorders
  • 9.2.1. Multiple Sclerosis
  • 9.2.2. Rheumatoid Arthritis
• 9.3. Cancer Treatment
  • 9.3.1. Hematologic Malignancies
  • 9.3.2. Solid Tumors
• 9.4. Infectious Diseases
  • 9.4.1. Bacterial Infections
  • 9.4.2. Viral Infections
• 9.5. Regenerative Medicine

10. Cell Therapy Market, by End User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Clinics
• 10.4. Commercial Laboratories
• 10.5. Hospitals

11. Americas Cell Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Cell Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Cell Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Pluri launches new cell therapy CDMO division
  • 14.3.2. Max Healthcare launches CAR-T cell therapy
  • 14.3.3. Bayer opens cell therapy manufacturing facility to advance regenerative medicines on a global scale
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Anterogen Co., Ltd.
• 2. Astellas Pharma Inc.
• 3. Athersys, Inc.
• 4. BioNTech SE
• 5. Bristol-Myers Squibb Company
• 6. Castle Creek Biosciences, Inc.
• 7. Catalent, Inc.
• 8. FUJIFILM Holdings Corporation
• 9. Gilead Sciences, Inc.
• 10. JCR Pharmaceuticals Co., Ltd.
• 11. Kolon TissueGene, Inc.
• 12. Lonza Group Ltd.
• 13. Medipost Co., Ltd.
• 14. Mesoblast Ltd.
• 15. Novartis AG
• 16. NuVasive, Inc.
• 17. Pfizer Inc.
• 18. Sartorius AG
• 19. Stemedica Cell Technologies, Inc.
• 20. Stempeutics Research Pvt. Ltd.
• 21. Takeda Pharmaceutical Company Limited
• 22. TegoScience
• 23. Thermo Fisher Scientific, Inc.
• 24. Vericel Corporation